
Guidelines of care for the management of cutaneous squamous cell carcinoma



Work Group: Murad Alam, MD, (Co-Chair),^a April Armstrong, MD, MPH,^b Christian Baum, MD,^c Jeremy S. Bordeaux, MD, MPH,^d Marc Brown, MD,^e Klaus J. Busam, MD,^f Daniel B. Eisen, MD,^g Vivek Iyengar, MD,^h Clifford Lober, MD, JD,ⁱ David J. Margolis, MD, PhD,^j Jane Messina, MD,^{k,l} Alexander Miller, MD,^m Stanley Miller, MD,ⁿ Eliot Mostow, MD, MPH,^o Christen Mowad, MD,^p Kishwer Nehal, MD,^q Kristi Schmitt-Burr,^r Aleksandar Sekulic, MD, PhD,^s Paul Storrs, MD,^h Joyce Teng, MD, PhD,^t Siegrid Yu, MD,^u Conway Huang, MD,^v Kevin Boyer, MPH,^w Wendy Smith Begolka, MBS,^w and Christopher Bichakjian, MD, (Co-Chair)^x

Invited Reviewers: John Y. S. Kim, MD,^y Jeffrey H. Kozlow, MD, MS,^z Bharat Mittal, MD,^{aa} Jeffrey Moyer, MD,^{bb} Thomas Olenecki, DO,^{cc} and Phillip Rodgers, MD^{dd}

Chicago and Schaumburg, Illinois; Denver, Colorado; Rochester, Minnesota; Cleveland, Rootstown, Burton, and Columbus, Ohio; Rochester and New York, New York; Sacramento, San Francisco, Yorba Linda, and Stanford, California; Kissimmee and Tampa, Florida; Philadelphia, Pennsylvania; Towson and Danville, Maryland; Phoenix, Arizona; Birmingham, Alabama; and Ann Arbor, Michigan.

Cutaneous squamous cell carcinoma (cSCC) is the second most common form of human cancer and has an increasing annual incidence. Although most cSCC is cured with office-based therapy, advanced cSCC poses a significant risk for morbidity, impact on quality of life, and death. This document provides evidence-based recommendations for the management of patients with cSCC. Topics addressed include biopsy techniques and histopathologic assessment, tumor staging, surgical and nonsurgical management, follow-up and prevention of recurrence, and management of advanced disease. The primary focus of these recommendations is on evaluation and management of primary cSCC and localized disease, but where relevant, applicability to recurrent cSCC is noted, as is general information on the management of patients with metastatic disease. (J Am Acad Dermatol 2018;78:560-78.)

Key words: biopsy; curettage; metastasis; phototherapy; radiotherapy; squamous cell carcinoma; staging; surgery; surveillance; topical therapy.

DISCLAIMER

Adherence to these guidelines will not ensure successful treatment in every situation. Furthermore, these guidelines should not be interpreted as setting

a standard of care, or be deemed inclusive of all proper methods of care, nor exclusive of other methods of care reasonably directed to obtaining the same results. The ultimate judgment regarding

From the Department of Dermatology,^a Department of Plastic and Reconstructive Surgery,^g and Department of Radiation Oncology, Northwestern University, Chicago^{aa}; Department of Dermatology, University of Colorado, Denver^b; Department of Dermatology, Mayo Clinic, Rochester^c; Case Western Reserve University School of Medicine, Cleveland^d; Department of Dermatology, University of Rochester, Rochester^e; Dermatopathology,^f Memorial Sloan-Kettering, New York^q; Department of Dermatology, University of California Davis, Sacramento^o; Private practice, Chicago^h; Private practice, Kissimmee^l; University of Pennsylvania Perelman School of Medicine, Philadelphia^j; Departments of Pathology, University of South Florida^k and Moffitt Cancer Center, Tampaⁱ; Private practice, Yorba Linda^m; Private practice, Towson, MDⁿ; Dermatology Section, NEOMED, Rootstown^p; Geisinger Medical Center, Danville^p; Basal Cell Carcinoma Nevus Syndrome Life Support Network, Burtonⁱ; Mayo Clinic, Phoenix^s; Stanford School of Medicineⁱ; Dermatologic Surgery and Laser Center, University of California San Francisco^l; Department of Dermatology, University of Alabama, Birmingham^v; American Academy of Dermatology,

Schaumburg, IL^w; Department of Dermatology, University of Michigan, Ann Arbor^x; Section of Plastic and Reconstructive Surgery,^z Department of Otolaryngology, Plastic/Head/Neck Surgery,^{bb} and Department of Family Medicine, University of Michigan, Ann Arbor^{dd}; and Department of Internal Medicine, Ohio State University, Columbus.^{cc}

Funding sources: None.

The management of conflict of interests for this guideline series complies with the Council of Medical Special Societies' *Code of Interactions with Companies*. The authors' conflict of interest/disclosure statements appear at the end of this article.

Accepted for publication October 3, 2017.

Reprint requests: guidelines@aad.org.

Correspondence to: Wendy Smith Begolka, MBS, American Academy of Dermatology, 930 East Woodfield Rd, Schaumburg, IL 60173. E-mail: wsmithbegolka@aad.org.

Published online January 10, 2018.

0190-9622/\$36.00

© 2017 by the American Academy of Dermatology, Inc.

<https://doi.org/10.1016/j.jaad.2017.10.007>

the propriety of any specific therapy must be made by the physician and the patient in light of all the circumstances presented by the individual patient, and the known variability and biologic behavior of the disease. This guideline reflects the best available data at the time the guideline was prepared. The results of future studies may require revisions to the recommendations in this guideline to reflect new data.

SCOPE

This guideline addresses the management of patients with cutaneous squamous cell carcinoma (cSCC) from the perspective of a US dermatologist. Other forms of SCC, such as head and neck (ie, mucosal) SCC are outside the scope of this document, as is a discussion of cSCC in situ (Bowen disease). The primary focus of the guideline is on the most commonly considered and utilized approaches for the surgical and medical treatment of cSCC, but it also includes recommendations on appropriate biopsy techniques, staging, follow-up, and prevention of cSCC. A detailed discussion of specific chemotherapeutic or radiotherapeutic approaches for distant metastatic SCC falls outside the scope of this guideline. However, general recommendations regarding the management of patients with advanced or metastatic SCC are included to provide guidance and facilitate consultation with a physician or multidisciplinary group with specific expertise in SCC, such as a surgical, medical, or radiation oncologist, head and neck surgeon, plastic surgeon, or dermatologist specializing in SCC.

METHODS

An expert work group was convened to determine the audience and scope of the guideline, and to identify important clinical questions in the biopsy, staging, treatment, and follow-up of cSCC (Table I). Work group members completed a disclosure of interests that was updated and reviewed for potential relevant conflicts of interest periodically throughout guideline development. If a potential conflict was noted, the work group member recused himself or herself from discussion and drafting of recommendations pertinent to the topic area of the disclosed interest.

An evidence-based approach was used and available evidence was obtained by using a systematic search and review of published studies from PubMed and the Cochrane Library databases from January 1960 through April 2015 for all identified clinical questions. A secondary search was subsequently undertaken to identify and review published studies from April 2015 to August 2016 to provide the most

Table I. Clinical questions used to structure the evidence review

-
- What is the standard grading system for BCC and cSCC?
 - What are the standard biopsy techniques for BCC and cSCC?
 - What pathologic and clinical information is useful in the pathology report for BCC and cSCC?
 - What are the benefits harm and effectiveness/efficacy of available treatments for BCC and cSCC?
 - Surgical treatment
 - Standard excision
 - Mohs micrographic surgery
 - Curettage and electrodesiccation
 - Cryosurgery
 - Topical therapy
 - Fluorouracil
 - Imiquimod
 - Other
 - Energy devices
 - Laser
 - Photodynamic therapy (MAL* and ALA)
 - Radiation therapy
 - What are effective treatment options for the management of advanced BCC and cSCC?
 - Hedgehog inhibitors*
 - What are the effective methods for follow-up and preventing recurrence and new primary keratinocyte cancer formation?
 - Oral and topical retinoids
 - Celecoxib
 - α -Difluoromethylornithine
 - Selenium
 - β -Carotene
-

ALA, Aminolevulinic acid; BCC, basal cell carcinoma; cSCC, cutaneous squamous cell carcinoma; MAL, methylaminolevulinate. *BCC only.

current information. Searches were prospectively limited to publications in the English language. As cSCC is traditionally known as a form of nonmelanoma skin cancer (NMSC), a term that also includes basal cell carcinoma (BCC), searches were collectively undertaken for literature on cSCC and BCC simultaneously, by using a set of search terms applicable to both cSCC and BCC. A parallel American Academy of Dermatology (AAD) guideline on BCC has also been developed.¹ MeSH (Medical Subject Headings) terms used in various combinations in the literature search included *carcinoma*, *basal cell carcinoma*, *squamous cell carcinoma*, *skin neoplasms*, *stage(ing)*, *grade(ing)*, *score(ing)*, *biopsy*, *pathology*, *prognosis*, *signs and symptoms*, *risk factors*, *curettage*, *electrodesiccation*, *excision*, *incomplete*, *cryosurgery*, *Mohs (micrographic) surgery*, *topical*, *fluorouracil*, *imiquimod*, *laser*, *radiotherapy*, *radiation*, *photocotherapy*,

Download English Version:

<https://daneshyari.com/en/article/8715217>

Download Persian Version:

<https://daneshyari.com/article/8715217>

[Daneshyari.com](https://daneshyari.com)